Integral Diagnostics Raised to Buy From Neutral by Citigroup >IDX.AU

Dow JonesMar 5 16:21 ET

Canaccord Genuity Upgrades Integral Diagnostics to Buy From Hold; Price Target Is AU$2.90

MT NewswiresFeb 27 04:24 ET

Bell Potter Sticks to Their Buy Rating for Integral Diagnostics Ltd. (IDX)

TipRanksFeb 26 18:12 ET

Integral Diagnostics Price Target Cut 7.4% to A$3.15/Share by Barrenjoey

Dow JonesFeb 26 15:50 ET

RBC Capital Remains a Buy on Integral Diagnostics Ltd. (IDX)

TipRanksJan 30 20:53 ET

Integral Diagnostics Price Target Raised 1.4% to A$3.50/Share by RBC Capital Markets

Dow JonesJan 29 17:41 ET

Jarden Sticks to Its Buy Rating for Integral Diagnostics Ltd. (IDX)

TipRanksDec 12, 2024 17:38 ET

Jarden Adjusts Integral Diagnostics' Price Target to AU$3.68 From AU$3.72, Keeps at Buy

MT NewswiresDec 11, 2024 03:13 ET

Integral Diagnostics Price Target Raised 10% to A$3.30/Share by Ord Minnett

Dow JonesSep 25, 2024 02:08 ET

Ord Minnett Sticks to Its Buy Rating for Integral Diagnostics Ltd. (IDX)

TipRanksSep 24, 2024 23:37 ET

Wall Street Analysts Are Bullish on Top Healthcare Picks

TipRanksSep 4, 2024 05:00 ET

Ord Minnett Sticks to Their Buy Rating for Integral Diagnostics Ltd. (IDX)

TipRanksAug 28, 2024 01:05 ET

Integral Diagnostics Raised to Overweight From Mkt Weight by Wilsons >IDX.AU

Dow JonesAug 27, 2024 19:04 ET

Integral Diagnostics Price Target Raised 11% to A$3.00/Share by Ord Minnett

Dow JonesAug 27, 2024 18:05 ET

Morgan Stanley Adjusts Integral Diagnostics' Price Target to AU$1.85 From AU$1.70, Keeps at Underweight

MT NewswiresMar 5, 2024 21:07 ET

Analysts Offer Insights on Healthcare Companies: Integral Diagnostics Ltd. (AU:IDX), Biophytis SA (Stuttgart: DE:6XB) and Merck KGaA (GB:0O14)

TipRanksMay 12, 2023 05:04 ET